Back to Search
Start Over
Off-label uses of TNFa inhibitors and IL12/23 inhibitors in dermatology
- Source :
- Dermatology Online Journal; vol 27, iss 11
- Publication Year :
- 2021
-
Abstract
- TNFa inhibitors, which include adalimumab, infliximab, etanercept, certolizumab, and golimumab, and IL12/23 inhibitor, ustekinumab, have been widely used as a U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. Outside of psoriasis, high levels of TNFa had also been found in several skin diseases including hidradenitis suppurativa. IL12 and IL23 play important role in the pathogenesis of SLE, alopecia areata, and vitiligo. This paper reviews the off-label uses of TNFa inhibitors and IL12/23 inhibitors in skin disorders.
Details
- Database :
- OAIster
- Journal :
- Dermatology Online Journal; vol 27, iss 11
- Notes :
- application/pdf, Dermatology Online Journal vol 27, iss 11
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1367497339
- Document Type :
- Electronic Resource